Control effect and mechanism of mangiferin on diabetic encephalopathy

A technology of diabetic encephalopathy and mangiferin, which is applied in the prevention and treatment of diabetic encephalopathy and the mechanism of mangiferin, can solve the problems of unseen production and sales, and achieve good medicinal prospects, strong effect, and the effect of inhibiting protein glycation

Inactive Publication Date: 2012-12-12
XUZHOU MEDICAL COLLEGE
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The use of mangiferin as a drug has no reports of production and sales at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Control effect and mechanism of mangiferin on diabetic encephalopathy
  • Control effect and mechanism of mangiferin on diabetic encephalopathy
  • Control effect and mechanism of mangiferin on diabetic encephalopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1: Effect of Mangiferin on Cognitive Function of DM Rats

[0027] 1 Materials and methods

[0028] 1.1 Experimental animals Male SD strain rats, 8-9 weeks old, 190-220g, were provided by the Experimental Animal Center of Xuzhou Medical College.

[0029]1.2 Drugs and reagents Mangiferin was purchased from Kunming Fengshanjian Pharmaceutical Research Co., Ltd. (purity>97%), STZ was purchased from sigma company, and glucose test kit was purchased from Nanjing Jiancheng Bioengineering Research Institute.

[0030] 1.3 Method

[0031] 1.3.1 Model establishment Male SD rats were fasted for more than 12 hours, and STZ (dissolved in 0.1mol / L sodium citrate buffer, pH 4.4 before use) was injected intraperitoneally at 55 mg / kg to establish a model. Three days after the injection, about 0.2 ml of blood was collected from the orbital venous plexus, centrifuged at 25°C and 3000 rpm for 10 minutes, and the serum was separated. Fasting blood glucose (FBG) was detected with a...

Embodiment 2

[0052] Example 2: Effect of mangiferin on the level of AGEs and the expression of its receptor RAGE in the hippocampus of DM rats

[0053] 1 Materials and methods

[0054] 1.1 Experimental animals are the same as in Example 1.

[0055] 1.2 Drugs and reagents Rabbit anti-RAGE antibody was purchased from Santa Cruz, USA; rabbit anti-GAPDH antibody was purchased from Bioworld, USA; type Ⅰ collagenase was purchased from Sigma, USA; secondary antibody to alkaline phosphatase, phenylmethylsulfonyl fluoride ( PMSF) and BCA protein test kit were purchased from Jiangsu Biyuntian Biological Company, Na 3 VO 4 and NaF were purchased from Sinopharm Group (Shanghai) Chemical Reagent Co., Ltd.

[0056] 1.3 Method

[0057] 1.3.1 Determination of AGEs level

[0058] The level of AGEs was detected by fluorescence spectrophotometry. The preserved hippocampus specimens were weighed and added to 10 times the amount (w / v) of 100mM PBS (pH7.4) buffer, and homogenized by ultrasonic at 4°C. Af...

Embodiment 3

[0073] Example 3: Effect of mangiferin on Glo-1 activity and protein expression in the hippocampus of DM rats

[0074] 1 Materials and methods

[0075] 1.1 Experimental animals are the same as in Example 1.

[0076] 1.2 Drugs and reagents Goat anti-Glo-1 antibody was purchased from American R&D System Company, rabbit anti-GAPDH antibody was purchased from American Bioworld Company, methylglyoxal was purchased from American Sigma Company, alkaline phosphatase secondary antibody, phenylmethylsulfonyl fluoride ( PMSF) and BCA protein test kit were purchased from Jiangsu Biyuntian Biological Company, Na 3 VO 4 , NaF and MgSO 4 Purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai), GSH was purchased from Shanghai Boyun Biotechnology Co., Ltd.

[0077] 1.3 Method

[0078] 1.3.1 Glo-1 activity assay

[0079]Glo-1 activity was determined by UV spectrophotometry. The homogenate of the hippocampus prepared when measuring the level of AGEs, and the supernatant obtained by...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to novel pharmacologic action of mangiferin, i.e., effects of mangiferin on preventing and treating diabetic encephalopathy. Mangiferin can obviously improve cognitive impairment caused by diabetes, remarkably reduce the level of advanced glycation endproducts (AGF) in the brain and expression of the acceptor RAGE thereof, substantially enhance activity and expression of glyoxalase 1 (Glo-1) in the brain, remarkably reduce the level of interleukin 1-beta (IL-1beta) and tumor necrosis factor alpha (TNF-alpha) in the brain, substantially improve the level of reduced glutathione (GSH) in the brain, remarkably reduce the level of malonaldehyde (MDA) in the brain, substantially improve the activity of superoxide dismutase (SOD) and the level of GSH in serum and substantially reduce the level of MDA in the serum. Mangiferin can be used for preventing and treating diabetic complications like diabetic encephalopathy.

Description

technical field [0001] The invention relates to new pharmacological action and action mechanism of mangiferin, especially the prevention and treatment effect of mangiferin on diabetic encephalopathy. Background technique [0002] Diabetic encephalopathy (Diabetic encephalopathy, DE) refers to the gradual occurrence of long-term diabetes mellitus (DM) patients with mental disorders characterized by mental decline and brain neurophysiological and structural changes. Most common complication. In diabetes, the structural changes of the brain are mainly the atrophy of the hippocampus and cortex, and the functional changes are mainly the impairment of cognitive function. A large number of research reports have confirmed the fact that diabetes causes cognitive dysfunction. In 2006, the term diabetes-associated cognitive decline (DACD) was proposed to further enhance people's understanding of this dysfunction and become the focus of research on diabetic encephalopathy. An estimate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P3/10A61P25/28
Inventor 刘耀武印晓星朱霞鲁茜魏雅芹尹家乐
Owner XUZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap